CT-155-R-001: The purpose of this study is to investigate if digital therapeutics (a moblie software application) can help treat certain symptoms of schizophrenia.
To evaluate the efficacy and safety of CT-155 in reducing experiential negative symptoms, compared with a Digital Control, in adult and late adolescent participants diagnosed with schizophrenia.
AOA DX is developing a blood test to detect ovarian cancer (biomarker). The purpose of this study is to collect and store donated blood samples and associated medical data from participating subjects to help develop the ovarian cancer test.
